Australia markets close in 1 hour 48 minutes
  • ALL ORDS

    7,392.70
    +67.50 (+0.92%)
     
  • ASX 200

    7,145.70
    +64.90 (+0.92%)
     
  • AUD/USD

    0.7845
    -0.0003 (-0.04%)
     
  • OIL

    65.21
    +0.31 (+0.48%)
     
  • GOLD

    1,833.40
    +2.10 (+0.11%)
     
  • BTC-AUD

    75,523.63
    +751.48 (+1.01%)
     
  • CMC Crypto 200

    1,565.04
    +129.26 (+9.00%)
     
  • AUD/EUR

    0.6451
    +0.0004 (+0.06%)
     
  • AUD/NZD

    1.0784
    +0.0012 (+0.11%)
     
  • NZX 50

    12,640.97
    -88.95 (-0.70%)
     
  • NASDAQ

    13,719.63
    +105.93 (+0.78%)
     
  • FTSE

    7,129.71
    +53.54 (+0.76%)
     
  • Dow Jones

    34,777.76
    +229.26 (+0.66%)
     
  • DAX

    15,399.65
    +202.95 (+1.34%)
     
  • Hang Seng

    28,517.48
    -93.17 (-0.33%)
     
  • NIKKEI 225

    29,532.96
    +175.14 (+0.60%)
     

Repare Therapeutics to Present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference on Tuesday, April 20 at 9:30 a.m. ET.

A live webcast of the presentation can be accessed in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for 30 days.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential best-in-class ATR inhibitor currently in Phase 1/2 clinical development, as well as RP-6306, a first-in-class, selective, oral inhibitor of PKMYT1 to treat CCNE1-amplified, FBXW7-altered and other PKMYT1 inhibitor-sensitive cancers, and a Polθ inhibitor program. For more information, please visit reparerx.com.

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005177/en/

Contacts

Repare:
Steve Forte
Chief Financial Officer
Repare Therapeutics Inc.
info@reparerx.com

Investors:
Kimberly Minarovich
Argot Partners
repare@argotpartners.com

Media:
David Rosen
Argot Partners
david.rosen@argotpartners.com
212-600-1902